{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:44:16Z","timestamp":1787316256261,"version":"build-2736575974"},"reference-count":17,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,9,24]],"date-time":"2012-09-24T00:00:00Z","timestamp":1348444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2013,6]]},"abstract":"Abstract<\/jats:title>\n \n Aim<\/jats:title>\n \n To assess thromboprophylaxis prescribing patterns against current guidelines and report thromboembolism (\n TE<\/jats:styled-content>\n ) incidence in multiple myeloma (\n MM)<\/jats:styled-content>\n patients treated with thalidomide (thal) or lenalidomide (len) at a specialist cancer hospital over a one\u2010year period.\n <\/jats:p>\n <\/jats:sec>\n \n Method<\/jats:title>\n \n Dispensing records of thal and len, diagnosis of\n MM<\/jats:styled-content>\n , patients\u2019 characteristics, disease status, co\u2010prescribed medicines including thromboprophylaxis and incidence of\n TE<\/jats:styled-content>\n were extracted from patients\u2019 records and a patient survey conducted to identify patients who sourced thromboprophylactic medicines outside the hospital.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Enoxaparin was most the commonly prescribed thromboprophylactic agent (43%), followed by low\u2010dose aspirin (26%) and therapeutic warfarin (6%). The thromboprophylactic strategy (including no prophylaxis) could not be determined for 22% of patients.\n TE<\/jats:styled-content>\n incidence (with any thromboprophylaxis) was 9.3 and 9.1% in thal\u2010based and len\u2010based regimens, respectively.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n Both aspirin and enoxaparin thromboprophylaxis were prescribed for patients on both low\u2010risk and high\u2010risk immunomodulatory drug\u2010based regimens, deviating from current consensus guidelines. Treatment of comorbidities constituted the rationale for maintenance on therapeutic warfarin. Fixed low\u2010dose warfarin was not prescribed.\n TE<\/jats:styled-content>\n event rates (with any thromboprophylaxis) were consistent with those reported in the literature. Documentation of a chosen strategy was lacking for nearly a quarter of patients, resulting in uncertainty of treatment plan for other members of the multidisciplinary treating team. Centers need to work towards evidence\u2010based institutional guidelines and improving documentation practices for thromboprophylaxis in their\n MM<\/jats:styled-content>\n patients.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/ajco.12013","type":"journal-article","created":{"date-parts":[[2012,9,24]],"date-time":"2012-09-24T03:52:30Z","timestamp":1348458750000},"page":"169-175","source":"Crossref","is-referenced-by-count":9,"title":["Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital"],"prefix":"10.1111","volume":"9","author":[{"given":"Marliese","family":"Alexander","sequence":"first","affiliation":[{"name":"Pharmacy Department Peter MacCallum Cancer Centre East Melbourne Victoria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khai C","family":"Teoh","sequence":"additional","affiliation":[{"name":"School of Pharmacy University of Queensland Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senthil","family":"Lingaratnam","sequence":"additional","affiliation":[{"name":"Pharmacy Department Peter MacCallum Cancer Centre East Melbourne Victoria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Kirsa","sequence":"additional","affiliation":[{"name":"Pharmacy Department Peter MacCallum Cancer Centre East Melbourne Victoria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D","family":"Mellor","sequence":"additional","affiliation":[{"name":"Pharmacy Department Peter MacCallum Cancer Centre East Melbourne Victoria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,9,24]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-117457"},{"key":"e_1_2_7_3_1","doi-asserted-by":"crossref","first-page":"427S","DOI":"10.1200\/jco.2006.24.18_suppl.7521","article-title":"Lenalidomide plus high\u2010dose dexamethasone provides improved overall survival compared to high\u2010dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of a North American phase III study (MM\u2010009) [abstract]","volume":"24","author":"Weber DM","year":"2006","journal-title":"J Clin Oncol"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-015909"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2817"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2008.09.008"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405062"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.6844"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.02059.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-344333"},{"key":"e_1_2_7_11_1","first-page":"404","article-title":"Lenalidomide and venous thrombosis in multiple myeloma","volume":"108","author":"Rajkumar SV","year":"2006","journal-title":"Blood"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68338-4"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.03.139"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61424-9"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.4065\/80.12.1568"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-02-0522"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190600799631"},{"key":"e_1_2_7_18_1","unstructured":"Commonwealth of Australia Department of Health and Aging.Pharmaceutical benefits schemen.d. [Cited 5 Jun 2011]. Available from:http:\/\/www.pbs.gov.au\/pbs\/home."}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajco.12013","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.12013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T22:50:46Z","timestamp":1697410246000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.12013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,24]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["10.1111\/ajco.12013"],"URL":"https:\/\/doi.org\/10.1111\/ajco.12013","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,24]]}}}